We are a Swiss law firm, dedicated to providing legal solutions to business, tax and regulatory matters.
Dedicated to our clients' success
Services
Intellectual Property
Life Sciences, Pharma, Biotech
Litigation and Arbitration
Meet our team
Our knowledge, expertise & publications
View all
Events
Deals & Cases
Careers
Fangda Carbon New Material Co., Ltd., an integrated carbon materials producer in in the People's Republic of China with diversified product offerings, including graphite electrodes, carbon blocks, isostatic graphite and iron ore concentrates, sold 22m global depositary receipts (GDRs) at an offer price of USD 8.63 per GDR and listed on 15 March 2023 a total number of 57'089'555 GDRs on the SIX Swiss Exchange (ISIN: US30712D1072, ticker: FDCB), thereby successfully tapping the Swiss capital market and raising gross proceeds of approximately USD 190m. Each GDR represents ten A shares of Fangda, which in turn are listed on the Shanghai Stock Exchange (600516.SH).
On 15 November 2022, Hangzhou GreatStar Industrial Co., Ltd., whose A Shares are listed on the Shenzhen Stock Exchange, became the eighth Chinese company that has listed global depositary receipts (GDRs) on the SIX Swiss Exchange.
On 28 July 2022, Ningbo Shanshan Co. raised USD 310.5m through GDRs issuance and listing on the SIX Swiss Exchange.
Novaremed AG, a privately held clinical-stage biopharmaceutical company and NeuroFront Therapeutics (Hong Kong) Limited, a China-based clinical stage neuroscience biotech company, jointly announced the signing of an exclusive collaboration and commercialization agreement for Novaremed’s innovative non-opioid investigational drug, NRD.E1, being developed for the treatment of diabetes-related neuropathic pain and other neuropathic pain indications.
Oculis S.A., a late-stage biopharmaceutical company, focused on developing transformative ophthalmic treatments to improve the sight and lives of patients, has closed an oversubscribed USD 57m Series C financing round.
Trustar Capital (formerly known as CITIC Capital Partners), a private equity affiliate of CITIC Capital Holdings Limited, has completed its over USD 50.0m investment in the Switzerland based global leading medical technology company MedAlliance SA ("MedAlliance"), becoming MedAlliance's single largest shareholder.
Polyphor AG (SIX: POLN) and Shanghai Fosun Pharmaceutical (Group) Co. Ltd ("Fosun Pharma", stock code: 600196.SH; 02196.HK), through its Swiss affiliate Fosun Pharmaceutical AG entered into an exclusive licensing agreement for...
Lamina Technologies SA acquired by Triton: The Yverdon based multi material cutting tools development company Lamina Technologies SA ("Lamina") was acquired on 14 May 2020 by Triton through its Triton Smaller Mid Cap Fund ("TSM")....
3SBio Inc.’s subsidiary Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (“Sunshine Guojian”) and Numab have formed a partnership focusing on the development and commercialization of a portfolio of novel multi-specific...
Suzhou, China and Pfäffikon SZ, Switzerland May 2, 2019 – CStone Pharmaceuticals ("CStone"; HKEX: 2616) and Numab Therapeutics AG ("Numab") have entered into an exclusive regional licensing agreement for the development and...
Displaying results 1 to 10 out of 13